WHO Sounds Alert Over Acute Lack of Obesity Injections
Under one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it releases its initial guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging broader and more equitable availability to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our new guidance recognises that obesity is a long-term condition that can be treated with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key obstacles to widespread access to the jabs that can assist patients in reducing significant body mass, notes the organization.
Weight-Loss Drug Shortage
Even under the present most favorable scenario, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – less than 10% of those who need them, per the health organization.
The advice encourages countries and companies to increase access, through strategies such as licensing agreements.
A patent on the active ingredient – the main ingredient of a leading brand – is due to expire in multiple nations in 2026.
The Way Obesity Drugs Operate
These medications imitate a body's own hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so people consume fewer calories.
Individuals usually begin shedding pounds after several weeks of commencing the weekly injections.
Evidence indicates people may put most of the weight back on a year later of discontinuing the drug, because their typical hunger return.
To be overweight or obese raises your likelihood for developing diseases, including type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity affects individuals in every country and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
